Thumbnail

亚太双胍市场——按药物和地理划分——增长、趋势和预测(2020 - 2025 年)

Looking to buy the report?

亚太地区国家糖尿病患病率较高。中国和印度占糖尿病人口的近 83%。到2045年,中国糖尿病人口预计将突破1.5亿。亚太地区大部分国家的2型糖尿病人口约占糖尿病人口的90%。不健康的饮食和久坐不动的生活方式正在推动中国超重和肥胖率的上升,而这本身就是发展为 2 型糖尿病的危险因素。中国超过三分之一的成年人超重,而7%的成年人肥胖。由于该地区大部分糖尿病患者为 2 型糖尿病患者,而双胍被认为是 2 型患者的一线药物,因此该地区的此类药物市场巨大。

                        

资料来源:魔多情报分析

在亚太地区双胍市场,2017年中国市场占比接近71.8%。到2023年,中国双胍市场规模将达到11.6912亿美元。越南在亚太地区双胍市场的复合年增长率最高,为 3.8%。在发展中国家,药物的低价是市场的驱动力。二甲双胍是双胍类的仿制药,因此这些药物的成本很低。再加上它是2型糖尿病患者的一线药物治疗,是该药在亚太地区销量高的主要原因。2017年亚太双胍市场为93.9413亿美元,预计在预测期内将达到107.2533亿美元。 

主要参与者:迈兰、梯瓦、武田、Ranbaxy/Sun Pharma、Dr Reddy's、默克、百时美施贵宝、勃林格殷格翰制药

主要发展:

2018 年 6 月:根据最近的科学研究,二甲双胍一直是用于治疗糖尿病的长期低成本药物,对大多数患有慢性肾病的患者来说是安全的。预计这将进一步推动该药物的销售。

2017 年 12 月:二甲双胍被认为是糖尿病患者的一线药物,现在也发现对糖尿病患者的孕妇是安全的。 

报告范围:

属性

细节

估计的基准年

2017

审查期

2012-2017

预测期

2018 – 2023

市场代表

2018 年至 2023 年的百万美元收入和复合年增长率

右:0in;text-align:justify">覆盖区域

亚太

报告覆盖率

收入预测和市场动态

购买本报告的理由:

  • 研究亚太地区当前和未来的市场前景。
  • 借助波特五力分析分析市场的各种观点
  • 预计将主导市场的细分市场的详细分析
  • 确定主要市场参与者采用的最新发展和策略
  • 3 个月的分析师支持,以及 excel 中的市场估算表

报告定制和好处:

可以自定义此报告以满足所需的要求。请与我们的分析师联系,他们将确保您获得适合您需求的报告。

1. Introduction

               1.1 Scope of Study

               1.2 Market Definition

               1.3 Executive Summary

2. Research Methodology

               2.1 Study Deliverables

               2.2 Study Assumptions

               2.3 Research Phases

3. Market Insights

               3.1 Technology Trends

               3.2 Industry Attractiveness - Porter's Five Forces Analysis

                              3.2.1 Bargaining Power of the Suppliers

                              3.2.2 Bargaining Power of the Consumers

                              3.2.3 Threat of New Entrants

                              3.2.4 Threat of Substitute Products and Services

                              3.2.5 Competitive Rivalry within the Industry

4.  Market Dynamics

               4.1 Drivers

               4.2 Restraints

               4.3 Opportunities

5. Market Indicators

               5.1 Total Diabetes Population

               5.2 Type 2 Diabetes Population

6. Market Segmentation and Analysis

               6.1 By Drug

                              6.1.1 Metformin

                                             6.1.1.1 Metformin, Revenue (2012-2023)

                                             6.1.1.2 Metformin, Volume (2012-2023)

7. Geographical Analysis

               7.1 Asia pacific

                              7.1.1 Australia

                                             7.1.1.1 Australia, Revenue (2012-2023)

                                             7.1.1.2 Australia, Volume (2012-2023)

                              7.1.2 India

                                             7.1.2.1 India, Revenue (2012-2023)

                                             7.1.2.2 India, Volume (2012-2023)

                              7.1.3 Indonesia

                                             7.1.3.1 Indonesia, Revenue (2012-2023)

                                             7.1.3.2 Indonesia, Volume (2012-2023)

                              7.1.4 Thailand

                                             7.1.4.1 Thailand, Revenue (2012-2023)

                                             7.1.4.2 Thailand, Volume (2012-2023)

                              7.1.5 Philippines

                                             7.1.5.1 Philippines, Revenue (2012-2023)

                                             7.1.5.2 Philippines, Volume (2012-2023)

                              7.1.6 Vietnam

                                             7.1.6.1 Vietnam, Revenue (2012-2023)

                                             7.1.6.2 Vietnam, Volume (2012-2023)

                              7.1.7 China

                                             7.1.7.1 China, Revenue (2012-2023)

                                             7.1.7.2 China, Volume (2012-2023)

                              7.1.8 South Korea

                                             7.1.8.1 South Korea, Revenue (2012-2023)

                                             7.1.8.2 South Korea, Volume (2012-2023)

                              7.1.9 Japan

                                             7.1.9.1 Japan, Revenue (2012-2023)

                                             7.1.9.2 Japan, Volume (2012-2023)

                              7.1.10 Malaysia

                                             7.1.10.1 Malaysia, Revenue (2012-2023)

                                             7.1.10.2 Malaysia, Volume (2012-2023)

                              7.1.11 Rest of Asia Pacific

                                             7.1.11.1 Rest of Asia Pacific, Revenue (2012-2023)

                                             7.1.11.2 Rest of Asia Pacific, Volume (2012-2023)

8. Key Player Profiles

               8.1 Dr Reddy's

               8.2 Lupin

               8.3 Teva

               8.4 Takeda

               8.5 Ranbaxy/Sun Pharma

               8.6 Bayer

               8.7 Mylan

               8.8 Merck

               8.9 Bristol-Myers Squibb

               8.10 Boehringer Ingelheim Pharmaceuticals

* Each Company Profile include overview, Revenue, Product and services, Swot, Recent Activities and strategic Analysis.

 

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy